The Company operates Beauty Clinics specializing in Aesthetic Skin, Body and Weight Management, Plastic Surgery, and Wellness based on modern medical principles that are approved by the US FDA.
| 6M24 | 6M23 | 2023 | 2022 |
|---|
| Revenues | 1,402.45 | 1,062.70 | 2,318.35 | 1,647.20 |
| Expenses | 1,212.94 | 884.32 | 1,953.02 | 1,390.34 |
| Net Profit (Loss) | 149.39 | 139.71 | 288.62 | 205.49 |
| Assets | 3,000.99 | 2,682.04 | 2,845.63 | 2,590.25 |
| Liabilities | 1,313.79 | 1,006.58 | 1,142.82 | 944.50 |
| Shareholders' Equity | 1,687.20 | 1,675.46 | 1,702.81 | 1,645.75 |
| Operating | 207.42 | 189.42 | 385.92 | 407.96 |
| Investing | 220.72 | -196.08 | -421.37 | -1,226.44 |
| Financing | -224.16 | -155.47 | -320.51 | 1,207.02 |
| EPS (Baht) | 0.68 | 0.64 | 1.31 | 1.21 |
| GP Margin (%) | 50.45 | 54.81 | 54.05 | 56.31 |
| NP Margin (%) | 10.65 | 13.15 | 12.45 | 12.48 |
| D/E Ratio (x) | 0.78 | 0.60 | 0.67 | 0.57 |
| ROE (%) | 17.74 | 25.63 | 17.24 | 22.75 |
| ROA (%) | 13.25 | 16.54 | 13.44 | 15.04 |
Vision
To be a leader on an international scale for Aesthetic, Plastic Surgery, and Wellness center through the use of medical and innovative services, aiming to be the best beauty provider in South East Asia
Key Strategic Highlights
- Strengthen further Brand Equity
- Optimize the Surgery Center
- Monetize the macro Health and Wellness trend
- Prioritize Innovation and Safety to ensure results
- Expand coverage of THE KLINIQUE and L.A.B. X
As of 30 June 2024, the Company has a total of 68 branches
- 44 THE KLINIQUE branches
- 21 L.A.B.X branches
- 1 L' Clinic
- 1 THE KLINIQUE SURGERY CENTER
- 1 KLINIQ MedSpa
The four service departments of the Company’s medical clinics and surgery center are Aesthetic Skin, Body & Weight Management, Plastic Surgery, and Wellness.
In Q2/2024, the Company’s total revenue from sales and services
was THB 701.61 million, increasing of 30.0% from Q2/2023 because of expanding 22 branches to reach customers easier, expanding the customer base of L.A.B.X brand to reach more customer groups, investing in medicines and medical equipment to provide a wide range of services and the growth of revenue from the KLINIQUE SURGERY CENTER which received good response from customers.
In Q2/2024, the Company opened a new 'THE KLINIQUE' branch at Central Phitsanulok and opened two new "L.A.B. X" branches at Seacon Bangkae and Mega Bangna.
- Risks of Competition in the Aesthetics Business
The Company has the policy to make a difference by focusing on creating a brand that consumers can recognize, focusing on providing a full range of services with cutting-edge medical innovations from Europe and the United States, developing the capabilities of personnel to meet the needs of consumers, and increasing branches nationwide to support consumer needs and to enable consumers to access our services.
- Risks from Changes in Treatment Technology
The Company focuses on quality by continuously investing in innovative and safe medical devices approved by the US FDA, considering the best safety standard. Considering our data since 2009, the average lifespan depends on the particular medical device, but mostly the device's shelf life is around 5-12 years, and still provides effective treatment. In addition, if the Company were to proceed with the purchase of medical devices exceeding THB 10 Million, a feasibility study must be conducted based on the payback period for such medical investment. Our management has regularly attended training & seminars related to research in treatment technology to monitor changes in various treatment technologies to develop the treatment technology. The Company also requires annual consumer needs surveys, such as looking at marketing data, conducting customer surveys, planning marketing schemes, and developing existing services to respond to consumer needs.
- The Golden Records Award: ASIA PACIFIC Highest Achievement and Thailand Top Achiever Award for Ulthera 2014 – 2022
- Top Galderma Iconic Clinic 2017-2022
- Editor's Choice: Best of Lip Filler from Sudsapda Beauty Awards 2022
- 20 Years Anniversary Celebration the Klinique No. 1 Botulinum Toxin Clinic 2023
- Etc.
| as of 28/06/24 | KLINIQ | SERVICE | mai |
|---|---|---|---|
| P/E (X) | 33.02 | 123.70 | 40.95 |
| P/BV (X) | 5.47 | 2.41 | 1.79 |
| Dividend yield (%) | 2.94 | 2.00 | 2.06 |
| 28/06/24 | 28/12/23 | 30/12/22 | |
|---|---|---|---|
| Market Cap (MB) | 9,735.00 | 9,240.00 | 8,525.00 |
| Price (B/Share) | 44.25 | 42.00 | 38.75 |
| P/E (X) | 33.02 | 34.05 | 42.78 |
| P/BV (X) | 5.47 | 5.68 | 5.26 |